Over the last two decades since the first breakthrough discoveries, such as the use of imatinib for chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) sarcomas and trastuzumab for ErbB2-positive breast cancers there has been an explosion of knowledge as to our understanding of the molecular genetics of malignancies (1-3).
